<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293096</url>
  </required_header>
  <id_info>
    <org_study_id>13-3174</org_study_id>
    <secondary_id>1K23GM110516-01</secondary_id>
    <nct_id>NCT02293096</nct_id>
  </id_info>
  <brief_title>Pharmacogenetic Prediction of Metoprolol Effectiveness</brief_title>
  <official_title>Pharmacogenetic Prediction of Metoprolol Effectiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will prospectively follow a population of patients with uncontrolled high
      blood pressure beginning metoprolol succinate therapy to determine the drug effect in an
      observational clinical trial. The investigators will determine each individual's genotype for
      both CYP2D6 and Adrenoceptor Beta 1 (ADRB1). Metabolomic markers will be identified to
      determine if specific metabolites are associated with drug response. The investigators'
      overall objective is to determine if genetics predicts metoprolol succinate response better
      than clinical factors such as age, race, body mass index, dose, and medication co-ingestion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure decline</measure>
    <time_frame>4-6 weeks status post initiation</time_frame>
    <description>10% decrease in SBP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate decline</measure>
    <time_frame>4-6 weeks</time_frame>
    <description>10 % decline from pre-initiation heart rate will considered a HR decline success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Occurrence of adverse drug events will be captured and stratified by CYP2D6 metabolizer status (PM, EM, IM, and UM) and by ADRB1 genotype (strong responder, good responder, non-responder).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Metabolomic Factors</measure>
    <time_frame>0-6 weeks</time_frame>
    <description>The top 5 metabolomic factors associated with SBP decline will be captured and stratified by CYP2D6 genotype and phenotype groups.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Metoprolol succinate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The parent study will integrate covariates to predict metoprolol effectiveness for SBP decline of 10%. All patients will receive metoprolol and groups the following covariates will be used to predict metoprolol effectiveness: clinical variables (Age, sex, race/ethnicity, co-medications, and BMI) CYP2D6 genotype, CYP2D6 phenotype, and metabolomic factors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotyping</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects compared on the outcome of metoprolol effectiveness for SBP decline stratified by CYP2D6 genotype.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP2D6 Phenotyping</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects compared on the outcome of metoprolol effectiveness for SBP decline stratified by CYP2D6 phenotype.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinical Factors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects compared on the outcome of metoprolol effectiveness for SBP based upon clinical factor prediction alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoprolol succinate</intervention_name>
    <arm_group_label>Metoprolol succinate</arm_group_label>
    <arm_group_label>Clinical Factors</arm_group_label>
    <other_name>Lopressor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genotyping</intervention_name>
    <description>CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete. Thus the investigator, the subject, and the outcomes investigator will be blind to the intervention.</description>
    <arm_group_label>Metoprolol succinate</arm_group_label>
    <arm_group_label>Genotyping</arm_group_label>
    <other_name>CYP2D6 genotyping and ADRB1 genotyping</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CYP2D6 Phenotyping</intervention_name>
    <description>Phenotype can be discordant from what is predicted by genotype due to variability in absorption, hepatic blood flow, drug interaction and drug elimination. These factors can be accounted for by utilizing a phenotyping assay that determines area under the curve of the probe since the probe is affected by the same variables dictating metabolism phenotype of the therapeutic drug. Investigators will be blind to the patient blood pressure outcome for this intervention.</description>
    <arm_group_label>Metoprolol succinate</arm_group_label>
    <arm_group_label>CYP2D6 Phenotyping</arm_group_label>
    <other_name>Dextromethorphan probe of CYP2D6</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects between age &gt;30 years and &lt; 80 years

          2. Subjects have diagnosis of uncontrolled essential hypertension.

        Exclusion Criteria:

          1. end stage liver disease,

          2. end stage renal disease,

          3. pregnant females,

          4. American Society of Anesthesiologists (ASA) classification of &gt;3,

          5. wards of the state, prisoners,

          6. decisionally challenged,

          7. HR&lt;60 bpm,

          8. AV block&gt;240 msec,

          9. active reactive airway disease,

         10. illicit drug abuse in the preceding 30 days,

         11. hypersensitivity to metoprolol or its derivatives

         12. severe peripheral arterial circulatory disorders.

        Subjects will have a screening physical exam performed by Dr. Monte prior to enrollment in
        the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Monte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Monte, MD</last_name>
    <phone>720-848-6777</phone>
    <email>andrew.monte@ucdenver.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lani Fink, BA</last_name>
    <phone>303-724-7871</phone>
    <email>lani.fink@ucdenver.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Denver; Emergency Department</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glenn McWilliams, BS</last_name>
      <phone>303-724-7871</phone>
      <email>glenn.mcwilliams@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Monte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2014</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genotype</keyword>
  <keyword>CYP2D6</keyword>
  <keyword>ADRB1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

